A study of KAN-004 for diarrhea or colitis from immunotherapy
Part of Digestive system clinical trials.
This trial tests a new treatment, KAN-004, for people with diarrhea or colon inflammation caused by cancer immunotherapy. It aims to help manage these side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor and received immunotherapy (at least 1 dose, within the last 180 days).
- You have moderate to severe diarrhea or colitis from immunotherapy (grade 2 or higher).
- You are 18 years or older.
- You can swallow capsules.
- You agree to give blood and stool samples, and can come for visits and follow-ups.
- If you could become pregnant or get someone pregnant, you agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether infliximab can treat stomach inflammation in the colon (colitis) or frequent diarrhea caused by immune checkpoint cancer drugs. It aims to improve symptoms safely for adults with certain solid cancers.
This study tests whether vedolizumab, a drug that reduces gut inflammation, can prevent diarrhea caused by immunotherapy (a type of cancer treatment). It is for adults with advanced melanoma, lung, or kidney cancer who have a stool marker of inflammation early in treatment.
This trial tests whether a treatment called fecal microbiota transplant (FMT) — transferring healthy gut bacteria — can help relieve diarrhea and colitis caused by immunotherapy drugs. If you have melanoma or kidney cancer and are experiencing diarrhea after immunotherapy, this study may offer a new option.
This early-phase study tests whether changing your gut bacteria with a fecal transplant can improve diarrhea or colitis caused by cancer immunotherapy. It may help people whose symptoms have not fully settled with standard treatments like steroids and other immune-blocking medicines.
This trial tests an investigational oral medication (SER-155) for people whose diarrhea is caused by immunotherapy. It aims to calm the gut and reduce symptoms without needing stronger drugs.
This trial tests if ustekinumab can help cancer patients who have diarrhea or colitis caused by immune checkpoint inhibitors. It may be an option if standard treatments haven't worked or aren't suitable.
Hear when a new Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.